Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inrebic

- PMLiVE

Bayer wins Company of the Year at PMEA 2016

Sees off strong competition from AbbVie, Celgene and Novartis

Bristol-Myers Squibb (BMS) building

Opdivo gets green light for Hodgkin lymphoma in Europe

Becomes the first PD-1 inhibitor to receive EU licence in this indication

Bristol-Myers Squibb (BMS) building

NICE backs BMS leukaemia drug Sprycel

Watchdog approves blood cancer therapy for use by NHS in England and Wales

- PMLiVE

Another late-stage setback tarnishes Gilead’s R&D lustre

Myelofibrosis drug candidate fails to best Incyte/Novartis’ Jakafi in phase III trials

Bristol-Myers Squibb (BMS) building

BMS teams up with Infinity Pharmaceuticals for Opdivo study

Will test dual therapy potential in targeting tumour resistance to checkpoint inhibitors

- PMLiVE

NICE set to knock-back Amgen’s myeloma treatment Kyprolis

Cites uncertainty in clinical and cost-effectiveness analyses

- PMLiVE

SMC approves Opdivo combo as first-line skin cancer treatment

Also backs Gilead’s Epclusa, Baxalta’s Oncaspar, AZ’s Lynparza and Amicus’ Galafold

Bristol Myers Squibb logo

BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

Cancer treatment approved by the MHRA for use before EU licence in place

Celgene building

Celgene engages IBM Watson for patient safety work

Aims to improve its pharmacovigilance methods with a new cloud-based platform

Bristol-Myers Squibb (BMS) building

Opdivo drives gain in BMS sales, but business revamp coming

Plans to invest in biologics production with potential divestment of older brands

- PMLiVE

Merck gets early OK for Keytruda in first-line lung cancer

FDA fast-tracks approval of PD-1/PD-L1 inhibitor for treatment of NSCLC

Bristol-Myers Squibb (BMS) building

Keytruda, Opdivo narrow Tecentriq’s lead in bladder cancer

BMS’ drug is currently under FDA and EMA review in advanced urothelial carcinoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links